PDUFA VI launches: Not Pluto flyby, but has potential
This article was originally published in Scrip
While the launch of the sixth round of the Prescription Drug User Fee Act (PDUFA), which officially got underway on 15 July, was far less dramatic than the Pluto flyby, the process ahead for the FDA and the biopharmaceutical industry, nonetheless, has the potential to boost scientific innovation and speed new therapies and cures to the market – helping to make life better for those down on Earth, declared Dr Stephen Ostroff, acting commissioner of the FDA.
You may also be interested in...
Regulators pledge to explore the use of real-world evidence, strengthen the patient's voice in drug review, and boost the agency's postmarketing surveillance abilities as part of sixth round of user fee program with industry.
Under round six of the user fee agreement with industry, the FDA is pledging to explore the use of real-world evidence, strengthen the patient's voice in the drug review process and boost the agency's postmarketing surveillance abilities.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.